TECHNOLOGY FOCUS - BIOTECHNOLOGY - Preferred Sequences: The polypeptide consists of SEQ ID NO: 2 or its fragment, having alpha-xylosidase activity. The polypeptide has pH optimum of 5-8.5 and temperature optimum of 40-65degreesC. The isolated polynucleotide has at least one mutation in the mature polypeptide coding sequence of SEQ ID NO: 1, in which the mutant nucleotide sequence encodes a polypeptide consisting of amino acids 1-796 of SEQ ID NO: 2.An isolated polynucleotide is obtained by hybridizing a population of DNA under high stringency conditions with:(i) nucleotides 1-2310 of SEQ ID NO: 1; or(ii) a complementary strand of (i), and isolating the hybridizing polynucleotide, which encodes a polypeptide having alpha-xylosidase activity.Preparation (claimed): Producing the polypeptide above comprises cultivating a cell, which in its wild-type form is capable of producing the polypeptide, under conditions for production of the polypeptide, and recovering the polypeptide.Alternatively, the method comprises cultivating a host cell comprising a nucleic acid construct comprising a nucleotide sequence encoding the polypeptide under conditions for production of the polypeptide, and recovering the polypeptide.Producing a polypeptide comprises cultivating a cell comprising the mutant polynucleotide of (7) encoding the polypeptide under conditions for production of the polypeptide, and recovering the polypeptide.Producing the polypeptide above comprises cultivating a transgenic plant or a plant cell comprising a polynucleotide encoding a polypeptide having alpha-xylosidase activity of the present invention under conditions for production of the polypeptide, and recovering the polypeptide.Preferred Method: Producing a polynucleotide having a mutant nucleotide sequence comprises introducing at least one mutation into the mature polypeptide coding sequence of SEQ ID NO: 1, where the mutant nucleotide sequence encodes a polypeptide consisting of amino acids 1-2310 of SEQ ID NO: 2, and recovering the polynucleotide comprising the mutant nucleotide sequence. Complete or partial removal of O-glycosylations of proteins within the EGF modules comprises contacting an O-glycosylated protein with one or more polypeptides selected from glycosidases such as alpha-xylosidases (EC 3.2.1.-), alpha-glucosidases (EC 3.2.1.20), glucoamylases (EC 3.2.1.3), beta-glucosidases (EC 3.2.1.21), or alpha-fucosidase (EC 3.2.1.51). The O-glycosylated proteins are involved in the coagulation cascade in mammals, where the O-glycosylated proteins are one or more of FVII, FVIIa, IX and IXa, thrombospondin, or plasma Protein Z. The O-glycosylated proteins are contacted with the polypeptide above.Producing a therapeutic protein comprises providing an O-glycosylated protein from a mammal host, and contacting the protein with one or more of the glycosidases or the polypeptide above, where the O-glycosylations of the protein are completely or partially removed.Degrading biomass comprises contacting the biomass with a polypeptide above. SPECIFIC SEQUENCES - The enzyme having alpha-xylosidase activity comprises a fully defined sequence comprising 769 bp (SEQ ID NO: 2), encoded by a polynucleotide, which comprises a nucleotide sequence comprising 2310 bp (SEQ ID NO: 1).    EXAMPLE - No relevant example given.